PTGX
Protagonist Therapeutics Inc
NASDAQ: PTGX · HEALTHCARE · BIOTECHNOLOGY
$98.97
+0.46% today
Updated 2026-04-30
Market cap
$6.34B
P/E ratio
—
P/S ratio
137.68x
EPS (TTM)
$-2.05
Dividend yield
—
52W range
$41 – $108
Volume
0.8M
Protagonist Therapeutics Inc (PTGX) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-282.80%
Operating margin
-677.00%
ROE
-20.20%
ROA
-14.00%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2014 | $0.00 | $-11.07M | — | — | — |
| 2015 | $0.00 | $-14.86M | — | — | — |
| 2016 | $0.00 | $-37.18M | — | — | — |
| 2017 | $20.06M | $-36.96M | 100.00% | -188.89% | -184.20% |
| 2018 | $30.93M | $-38.92M | 100.00% | -136.68% | -125.87% |
| 2019 | $231000.00 | $-77.19M | 100.00% | -34,857.58% | -33,414.29% |
| 2020 | $28.63M | $-66.15M | 100.00% | -225.36% | -231.07% |
| 2021 | $27.36M | $-125.55M | 100.00% | -460.01% | -458.94% |
| 2022 | $26.58M | $-123.41M | 100.00% | -494.24% | -464.29% |
| 2023 | $60.00M | $-78.95M | 100.00% | -156.09% | -131.59% |
| 2024 | $434.43M | $275.19M | 100.00% | 58.20% | 63.34% |
| 2025 | $46.02M | $-130.15M | 97.34% | -343.63% | -282.83% |